Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis for six months ended June 30, 2026
In April 2026, AbbVie announced the submission of an application to the U.S. FDA for Skyrizi for subcutaneous induction for the treatment of adult patients with moderately to severely active CD
In June 2026, AbbVie announced the U.S. FDA approved Skyrizi for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on · in our words, not the filing’s